Fig. 6
From: Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
Long-term BTKi treatment normalises CD8 + and CD4 + exhaustion marker expression in dividing T cells. Proliferation of PBMC from CLL patients collected at baseline or after long-term treatment of ibrutinib (n = 7) or zanubrutinib (n = 8), and healthy donor (HD, n = 7). PD-1, TIM3 and LAG3 cell surface expression (MFI) was measured on individual generations of dividing cells (A–F) after 5 days stimulation. Data was analysed using Mann–Whitney (HD vs patient sample) or Wilcoxon matched-pairs signed rank (baseline vs treatment sample) tests